secwatch.observer — SEC 8-K summary
======================================

Issuer:     PARKERVISION INC (PRKR)
CIK:        0000914139
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001437749-23-018338
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ParkerVision appoints Lewis Titterton as Class II director
----------------------------------------------------------

- Effective June 22, 2023, Titterton fills a board vacancy; he previously served from Sept 2018 to Apr 2019.
- Titterton is lead independent director at Anixa Biosciences (ANIX) and chaired NYMED's board.
- CEO Jeffery Parker praised Titterton's biotech background as relevant to ParkerVision's licensing strategy.
- Company entered a standard indemnification agreement with Titterton.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914139/000143774923018338/0001437749-23-018338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914139/000143774923018338/prkr20230624_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-018338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer